Hologic has been acquired by Blackstone and TPG for $18.3 billion, marking the largest medtech buyout since 2006, which highlights the growing investor interest in women’s health.

Target Information

Hologic, a leader in women's health diagnostics and devices, has been acquired by Blackstone and TPG for $18.3 billion, equating to $76 per share in cash. Following the completion of this transaction, Hologic will be delisted from Nasdaq. This purchase price reflects a notable premium of approximately 46% over Hologic’s closing share price on May 23, 2025, which was the final trading session prior to media announcements regarding the impending acquisition.

This marks the largest acquisition in the medtech sector since 2006, made possible by improving conditions in credit markets and a consortium of banks willing to finance substantial investments in robust, burgeoning sectors like women's health.

Industry Overview

Hologic operates in a significant segment of the medical technology industry focused on women's health, which has gained substantial traction and recognition. The collective markets for Breast Health, GYN Surgical, and Skeletal Health exhibit cons